On the other hand, specific inhibitors of LSD1 have been proposed as a potential alternative due to the aberrant expression of LSD1 in several types of cancer such as breast [21, 22], colorectal [23], neuroblastoma [24], osteosarcoma, rhabdomyosarcoma, and synovial sarcoma [25, 26]. Here, KDM1A is linked to rhabdomyosarcoma.